Constellation Pharmaceuticals Inc (CNST)
Constellation Pharmaceuticals Inc
NASDAQ:CNST (7/14/2021, 7:14:04 PM)
After market: 33.99 0 (0%)33.99
+0.02 (+0.06%)
Company Profile
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company is headquartered in Cambridge, Massachusetts and currently employs 154 full-time employees. The company went IPO on 2018-07-19. The firm has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The firm is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.
Company Info
Constellation Pharmaceuticals Inc
215 1st St Ste 200
Cambridge MASSACHUSETTS 02142
P: 16177140555.0
CEO: Jigar Raythatha
Employees: 154.0
Website: https://www.constellationpharma.com/
CNST News
3 years ago - MorphoSys AGMorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-OncologyCompany Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its previously announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) ("Constellation") for $34.00 per share, net to
3 years ago - Market News VideoInteresting CNST Put Options For August 20th
3 years ago - Capital Market LaboratoriesA Buy the Dip Stock Trigger in Constellation Pharmaceuticals IncThe Techncial Trigger Driven Stock Trade in Constellation Pharmaceuticals Inc (NASDAQ:CNST) .
3 years ago - Halper Sadeh LLPINVESTIGATION ALERT: Halper Sadeh LLP Investigates IKNX, MPB, JAX, CNST; Shareholders are Encouraged to Contact the Firm3 years ago - MorphoSys AGMorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation PharmaceuticalsMUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation Pharmaceuticals, Inc., (NASDAQ:CNST) ("Constellation"). The expiration of the HSR waiting period satisfies one of the conditions to the tender offer, which is
3 years ago - Lifshitz Law Firm, P.C.Lifshitz Law Firm, P.C. Announces Investigation of CNST, FFWM, SLCT, and GRACNST Twits
Here you can normally see the latest stock twits on CNST, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
